References
- Lloyd-Jones D, Adams RJ, Brown TM et al. American Heart Association statistics committee and stroke statistics subcommittee. Executive summary: heart disease and stroke statistics – 2010 update: a report from the American Heart Association. Circulation121, 948–954 (2010).
- Lip GY, Tse HF. Management of atrial fibrillation. Lancet370, 604–618 (2007).
- Roe MT, Messenger JC, Weintraub WS et al. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J. Am. Coll. Cardiol.56, 254–263 (2010).
- Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med.357, 2001–2015 (2007).
- Wallentin L, Becker RC, Budaj A et al. PLATO investigator. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med.361, 1045–1057 (2009).
- Hohnloser SH, Crijns HJ, van Eickels M et al. ATHENA investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N. Engl. J. Med.360, 668–678 (2009).
- Connolly SJ, Camm AJ, Halperin JL et al. The PALLAS Investigators. Dronedarone in high-risk permanent atrial fibrillation. N. Engl. J. Med.365(24), 2268–2276 (2011).
- Diener HC, Bogousslavsky J, Brass LM et al. MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet364, 331–337 (2004).
- Mega JL, Braunwald E, Wiviott SD et al. The ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med.366(1), 9–19 (2012).
- Tricoci P, Huang Z, Held C et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N. Engl. J. Med.366(1), 20–33 (2012).
- Kozlowski D, Budrejko S, Lip GYH et al. Dronedarone: an overview. Ann. Med. doi:10.3109/07853890.2011.594808 (2011) (Epub ahead of print).
- Goldhaber S, Leizorovicz, A, Kakkar AK et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N. Engl. J. Med.365(23), 2167–2177 (2011).
- Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovasculardisease. Thromb. Haemost.104, 49–60 (2010).
- Pengo V, Crippa L, Falanga A et al. Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb. Haemost.106, 868–876 (2011).
- Alexande J, Lopes RD, James S et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N. Engl. J. Med.365(8), 699–708 (2011).
- Lip GY, Huber K, Andreotti F et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb. Haemost.103, 13–28 (2010).
- Faxon DP, Eikelboom JW, Berger PB et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb. Haemost.106, 572–584 (2011).
- Huber K, Airaksinen KJ, Cuisset T, Marín F, Rubboli A, Lip GY. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb. Haemost.106(4), 569–571 (2011).